Effect of Ginkgo biloba extract on procarcinogen-bioactivating human CYP1 enzymes: Identification of isorhamnetin, kaempferol, and quercetin as potent inhibitors of CYP1B1

Toxicology and Applied Pharmacology

Volumn 213, Issue 1, 2006, Pages 18-26

  Chang, Thomas K H ^a   Chen, Jie ^a   Yeung, Eugene Y H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Bilobalide; CYP1A1; CYP1A2; CYP1B1; Cytochrome P450; Ginkgo biloba; Ginkgolide A; Ginkgolide B; Ginkgolide C; Ginkgolide J; Isorhamnetin; Kaempferol; Quercetin

Indexed keywords

BENZO[A]PYRENE; BILOBALIDE; CARCINOGEN; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 INHIBITOR; ETHOXYRESORUFIN; FLAVONOID GLYCOSIDE; FLAVONOL DERIVATIVE; GINKGO BILOBA EXTRACT; GINKGOLIDE A; GINKGOLIDE B; GINKGOLIDE C; GINKGOLIDE J; GK 501; ISORHAMNETIN; ISORHAMNETIN 3 O RUTINOSIDE; KAEMPFEROL; LACTONE DERIVATIVE; NICOTIFLORIN; QUERCETIN; RUTOSIDE; TERPENE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CATALYST; COMPETITIVE INHIBITION; CONTROLLED STUDY; DEALKYLATION; DRUG IDENTIFICATION; DRUG POTENCY; ENZYME INHIBITION; ENZYME MECHANISM; GINKGO BILOBA; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER MICROSOME;

ARYL HYDROCARBON HYDROXYLASES; BENZO(A)PYRENE; CARCINOGENS; CATALYSIS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; DEALKYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOLS; GINKGO BILOBA; HUMANS; HYDROXYLATION; KAEMPFEROLS; MICROSOMES, LIVER; PLANT EXTRACTS; QUERCETIN; RECOMBINANT PROTEINS;

GINKGO BILOBA;

EID: 33646131391     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2005.09.007     Document Type: Article

References (41)

1. Agha A.M., El-Fattah A.A.A., Al-Zuhair H.H., and Al-Rikabi A.C. Chemopreventive effect of Ginkgo biloba extract against benzo[a]pyrene-induced forestomach carcinogenesis in mice: amelioration of doxorubicin cardiotoxicity. J. Exp. Clin. Cancer Res. 20 (2001) 39-50
2. Bedir E., Tatli I.I., Khan R.A., Zhao J., Takamatsu S., Walker L.A., Goldman P., and Khan I.A. Biologically active secondary metabolites from Ginkgo biloba. J. Agric. Food Chem. 50 (2002) 3150-3155
3. Blumenthal M. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines (1998), Integrative Medicine Communications, Boston, MA
4. Burke M.D., and Mayer R.T. Ethoxyresorufin: direct fluorimetric assay of a microsomal O-dealkylation which is preferentially inducible by 3-methylcholanthrene. Drug Metab. Dispos. 2 (1974) 583-588
5. Burke M.D., Thompson S., Weaver R.J., Wolf C.R., and Mayer R.T. Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem. Pharmacol. 48 (1994) 923-936
6. Chan H.Y., Chen Z.Y., Tsang D.S.C., and Leung L.K. Baicalein inhibits DMBA-DNA adduct formation by modulating CYP1A1 and CYP1B1 activities. Biomed. Pharmacother. 56 (2002) 269-275
7. Chang T.K.H., Lee W.B.K., and Ko H.H. Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1. Can. J. Physiol. Pharmacol. 78 (2000) 874-881
8. Chang T.K.H., Chen J., and Lee W.B.K. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J. Pharmacol. Exp. Ther. 299 (2001) 874-882
9. Chang T.K.H., Chen J., and Benetton S.A. In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. Drug Metab. Dispos. 30 (2002) 378-384
10. Chang T.K.H., Chen J., Pillay V., Ho J.Y., and Bandiera S.M. Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver. Toxicol. Sci. 71 (2003) 11-19
11. Chun Y.J., Kim S., Kim D., Lee S.K., and Guengerich F.P. A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res. 61 (2001) 8164-8170
12. Doostdar H., Burke M.D., and Mayer R.T. Bioflavonoids: selective substrates and inhibitors for cytochromes P450 CYP1A and CYP1B1. Toxicology 144 (2000) 31-38
13. Gaudineau C., Beckerman R., Welbourn S., and Auclair K. Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem. Biophys. Res. Commun. 318 (2004) 1072-1078
14. Guengerich F.P., Chun Y.J., Kim D., Gillam E.M.J., and Shimada T. Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. Mutat. Res. 523-524 (2003) 173-182
15. Gurley B.J., Gardner S.F., Hubbard M.A., Williams D.K., Gentry W.B., Cui Y., and Ang C.Y.W. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in human. Clin. Pharmacol. Ther. 72 (2002) 276-287
16. Gurley B.J., Gardner S.F., Hubbard M.A., Williams D.K., Gentry W.B., Cui Y., and Ang C.Y.W. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly. St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 22 (2005) 525-539
17. Kuo I.F., Chen J., and Chang T.K.H. Effect of Gingko biloba extract on rat hepatic microsomal CYP1A enzyme activity: role of ginkgolides, bilobalide, and flavonols. Can. J. Physiol. Pharmacol. 82 (2004) 57-64
18. Lewis D.F.V. 57 varieties: the human cytochromes P450. Pharmacogenomics 5 (2004) 305-318
19. Maclennan K.M., Darlington C.L., and Smith P.F. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog. Neurobiol. 67 (2002) 235-257
20. Mammen J.S., Kleiner H.E., DiGiovanni J., Sutter T.R., and Strickland P.T. Coumarins are competitive inhibitors of cytochrome P450 1B1, with equal potency for allelic variants. Pharmacogenet. Genomics 15 (2005) 183-188
21. McFadyen M.C.E., Melvin W.T., and Murray G.I. Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol. Cancer Ther. 3 (2004) 363-371
22. McGovern S.L., Caselli E., Grigorieff N., and Shoichet B.K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 45 (2002) 1712-1722
23. Murray G.I., Taylor M.C., McFadyen M.C.E., Mckay J.A., Greenlee W.F., Burke M.D., and Melvin W.T. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 57 (1997) 3026-3031
24. Muskhelishvili L., Thompson P.A., Kusewitt D.F., Wang C., and Kadlubar F.F. In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues. J. Histochem. Cytochem. 49 (2001) 229-236
25. Nebert D.W., and Gelboin H.V. Substrate-inducible microsomal aryl hydroxylase in mammalian cell culture: I. Assay and properties of induced enzyme. J. Biol. Chem. 243 (1964) 6242-6249
26. Pastrakuljic A., Tang B.K., Roberts E.A., and Kalow W. Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem. Pharmacol. 53 (1997) 531-538
27. Rendic S., and Di Carlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29 (1997) 413-580
28. Roberts D.W., Doerge D.R., Churchwell M.I., Da Costa G.G., Marques M.M., and Tolleson W.H. Inhibition of extrahepatic human cytochromes P450 1A1 and 1B1 by metabolism of isoflavones found in Trifolium pratense (Red Clover). J. Agric. Food Chem. 52 (2004) 6623-6632
29. Schwarz D., Kisselev P., and Roots I. St. John's wort extracts and some of their constituents potently inhibit ultimate carcinogen formation from benzo[a]pyrene-7,8-diol by human CYP1A1. Cancer Res. 63 (2003) 8062-8068
30. Shimada T., and Fujii-Kuriyama Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci. 95 (2004) 1-6
31. Shimada T., Hayes C.L., Yamazaki H., Amin S., Hecht S.S., Guengerich F.P., and Sutter T.R. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res. 56 (1996) 2979-2984
32. Shimada T., Gillam E.M.J., Sutter T.R., Strickland P.T., Guengerich F.P., and Yamazaki H. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab. Dispos. 29 (1997) 617-622
33. Takahashi E., Fujita K., Kamataki T., Arimoto-Kobayashi S., Okamoto K., and Negishi T. Inhibition of human cytochrome P450 1B1, 1A1 and 1A2 by antigenotoxic compounds, purpurin and alizarin. Mutat. Res. 508 (2002) 147-156
34. Tatemichi M., Nomura S., Ogura T., Sone H., Nagata H., and Esumi H. Mutagenic activation of environmental carcinogens by microsomes of gastric mucosa with intestinal metaplasia. Cancer Res. 59 (1999) 3893-3898
35. van Beek T.A. Chemical analysis of Ginkgo biloba leaves and extracts. J. Chromatogr., A 967 (2002) 21-55
36. von Moltke L.L., Weemhoff J.L., Bedir E., Khan I.A., Harmatz J.S., Goldman P., and Greenblatt D.J. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J. Pharm. Phamacol. 56 (2004) 1039-1044
37. Walle T. Absorption and metabolism of flavonoids. Free Radical Biol. Med. 36 (2004) 829-837
38. Webb J.L. Enzyme and Metabolic Inhibitors (1963), Academic Press, New York
39. Wojcicki J., Gawronska-Szklarz G., Bieganowski W., Patalan M., Smulski H., Samochowiec L., and Zakrzewski J. Comparative pharmacokinetics and bioavailability of flavonoid glycosides of Ginkgo biloba after a single oral administration of three formulations to healthy volunteers. Mater. Med. Pol. 27 (1995) 141-146
40. Zhai S., Dai R., Friedman F.K., and Vestal R.E. Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids. Drug Metab. Dispos. 26 (1998) 989-992
41. Zou L., Harkey M.R., and Henderson G.L. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 71 (2002) 1579-1589